Demographics and patient characteristics
| . | . |
|---|---|
| Age (mo) at start of etoposide, median (range) | 20 (0-282) |
| Gender, n (%) | |
| Male | 52 (58) |
| Female | 37 (42) |
| Active CNS disease at diagnosis, n (%) | 22 (25) |
| Genetics, n (%) | |
| Positive | 44 (49) |
| Indeterminant/ambiguous | 15 (17) |
| Negative | 29 (33) |
| Not obtained | 1 (1) |
| Underlying rheumatologic diagnosis or MAS, n (%) | 9 (10) |
| Received BMT, n (%) | 55 (62) |
| Days to BMT, median (range) | 124 (56-2120) |
| Surviving >1 y without BMT | 22 (25) |
| Salvage therapy/reintensification, n (%) | |
| Within 100-d study period | 28 (31) |
| Within 1 y of treatment initiation | 37 (42) |
| Pre-BMT mortality (survived to BMT or 1 y), n (%) | |
| Survived | 77 (87) |
| Died | 12 (13) |
| OS, n (%) | |
| Survived | 65 (73) |
| Died | 24 (27) |
| . | . |
|---|---|
| Age (mo) at start of etoposide, median (range) | 20 (0-282) |
| Gender, n (%) | |
| Male | 52 (58) |
| Female | 37 (42) |
| Active CNS disease at diagnosis, n (%) | 22 (25) |
| Genetics, n (%) | |
| Positive | 44 (49) |
| Indeterminant/ambiguous | 15 (17) |
| Negative | 29 (33) |
| Not obtained | 1 (1) |
| Underlying rheumatologic diagnosis or MAS, n (%) | 9 (10) |
| Received BMT, n (%) | 55 (62) |
| Days to BMT, median (range) | 124 (56-2120) |
| Surviving >1 y without BMT | 22 (25) |
| Salvage therapy/reintensification, n (%) | |
| Within 100-d study period | 28 (31) |
| Within 1 y of treatment initiation | 37 (42) |
| Pre-BMT mortality (survived to BMT or 1 y), n (%) | |
| Survived | 77 (87) |
| Died | 12 (13) |
| OS, n (%) | |
| Survived | 65 (73) |
| Died | 24 (27) |
CNS, central nervous system; MAS, macrophage activation syndrome.